Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion NASDAQ: BMEA reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for weight management. The company said the 28-day study showed weight reduction across active-treatment cohorts, while reported gastrointestinal adverse events were mild or moderate.
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Eli Lilly: Buy The GLP-1 Growth Premium
Eli Lilly is building a dominant obesity and diabetes treatment portfolio, positioning itself as a high-growth, premium-valued pharmaceutical company. LLY's tirzepatide-based products, Mounjaro and Zepbound, drive nearly $15 billion in revenue with 91% and 46% YoY growth, respectively. I assign a buy rating to LLY, justifying its 25x EV/EBITDA premium by 20%+ annual sales growth and robust free cash flow expansion.
Should Value Investors Buy Global Partners (GLP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues to chip away at the company's position in the market – including in the burgeoning obesity pill space.
NTHM ETF Rotates Into Midstream Energy & GLP-1 Healthcare
The NBI Thematic Rotation ETF (NTHM:TSX) has completed its latest portfolio rebalance, pivoting away from broad tech and industrial momentum to channel capital into midstream energy infrastructure and GLP-1 weight-loss drug manufacturers. The fund tracks the Thematic Rotation Quality Momentum Screened Index (TRQMS).
WW International Eyes Cash Flow Turnaround as GLP-1 Care Gains Momentum
WW International NASDAQ: WW executives outlined the company's efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.
Are Investors Undervaluing Global Partners (GLP) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP)
Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
Lilly's Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
Eli Lilly and Company TodayLLYEli Lilly and Company$1,171.40 +11.40 (+0.98%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$712.05▼$1,292.65Dividend Yield0.59%P/E Ratio39.28Price Target$1,292.18Add to WatchlistOn Aug. 31, Eli Lilly & Co. NYSE: LLY announced its intention to acquire Merida Biosciences for $2.875 billion.
